Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edivoxetine as Adjunctive Therapy to SSRI in MDD Symptom Re-emergence Prevention
NCT01299272Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of edivoxetine in major depressive disorder (MDD), sponsored by Eli Lilly and Company. Started May 2011; status: completed.
02
Drugs
edivoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01299272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01299272.